Outset Medical, Inc. (OM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM). Investors who purchased Outset securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Outset and certain of its officers and/or directors have violated federal securities laws.
On June 13, 2022, Outset released a report with its guidance for the second quarter of 2022. It also said that it “implemented a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending the Food and Drug Administration’s (“FDA”) review and clearance of a 510(k) the Company submitted for changes made since the device’s original March 2020 clearance.” Following this news, Outset stock dropped $5.02 per share, or about 24.6%, to open at $15.39 on June 14, 2022.
If you are aware of any facts relating to this investigation or purchased Outset shares you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.